Company / SG&A Expense
Vertex Pharmaceuticals SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.8B
FY2025
5-year range
$840.1M / $1.8B
FY2021-FY2025
Trend
+19.7%
vs FY2024
Sector context
#16 of 213
Health Care
What the data says
Among 213 Health Care companies, Vertex Pharmaceuticals is in the bottom 8% for sg&a expense. SG&A Expense has increased for 9 consecutive years, from $433M in FY2016 to $1.8B in FY2025.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +17.9%. Top quartile in the Health Care sector.
Increased from $1.1B to $1.8B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +22.9%
- 5-Year CAGR
- +17.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $1.8B Sector average $722.3M
▼
+142.7% above sector average
Key checks
Key Insights
- Vertex Pharmaceuticals's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +17.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 19.7% year-over-year.
- Ranks #16 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +19.7% |
| FY2024 | $1.5B | +28.8% |
| FY2023 | $1.1B | +20.3% |
| FY2022 | $944.7M | +12.5% |
| FY2021 | $840.1M | +9.0% |
| FY2020 | $770.5M | +17.0% |
| FY2019 | $658.5M | +18.1% |
| FY2018 | $557.6M | +12.4% |
| FY2017 | $496.1M | +14.6% |
| FY2016 | $432.8M | +14.9% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026